DE60004496D1 - Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff - Google Patents

Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Info

Publication number
DE60004496D1
DE60004496D1 DE60004496T DE60004496T DE60004496D1 DE 60004496 D1 DE60004496 D1 DE 60004496D1 DE 60004496 T DE60004496 T DE 60004496T DE 60004496 T DE60004496 T DE 60004496T DE 60004496 D1 DE60004496 D1 DE 60004496D1
Authority
DE
Germany
Prior art keywords
liquid vaccine
threalose
stabilize
vaccine composition
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60004496T
Other languages
English (en)
Other versions
DE60004496T2 (de
Inventor
Graf Sandrine Lentsch
Jean-Rene Cartier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Application granted granted Critical
Publication of DE60004496D1 publication Critical patent/DE60004496D1/de
Publication of DE60004496T2 publication Critical patent/DE60004496T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60004496T 1999-03-23 2000-03-23 Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff Expired - Fee Related DE60004496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (fr) 1999-03-23 1999-03-23 Utilisation de trehalose pour stabiliser un vaccin liquide
FR9903765 1999-03-23
PCT/FR2000/000730 WO2000056365A1 (fr) 1999-03-23 2000-03-23 Utilisation de trehalose pour stabiliser un vaccin liquide

Publications (2)

Publication Number Publication Date
DE60004496D1 true DE60004496D1 (de) 2003-09-18
DE60004496T2 DE60004496T2 (de) 2004-04-08

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60004496T Expired - Fee Related DE60004496T2 (de) 1999-03-23 2000-03-23 Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Country Status (11)

Country Link
EP (1) EP1163008B1 (de)
JP (1) JP2002540079A (de)
AT (1) ATE246937T1 (de)
AU (1) AU3438900A (de)
CA (1) CA2366869A1 (de)
DE (1) DE60004496T2 (de)
DK (1) DK1163008T3 (de)
ES (1) ES2200845T3 (de)
FR (1) FR2791895B1 (de)
PT (1) PT1163008E (de)
WO (1) WO2000056365A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
EP2191844B1 (de) 2003-01-30 2014-03-05 Novartis AG Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB2451216B (en) * 2006-05-12 2011-05-04 Bharat Biotech Int Ltd A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
EP2106788A1 (de) * 2008-04-04 2009-10-07 Ipsen Pharma Flüssige und lyophilisierte Formulierungen
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
CN103002910A (zh) 2010-03-10 2013-03-27 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
EP2524701A3 (de) 2011-05-20 2012-12-19 Nitto Denko Corporation Pharmazeutische Zusammensetzung und Herstellungsverfahren dafür
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
EP2788477A2 (de) 2011-12-07 2014-10-15 Institut Pasteur Identifizierung des porcinen parecho-like virus und anwendungen
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
FR2992656B1 (fr) 2012-07-02 2016-10-07 Sanofi Pasteur Procede de production d'antigenes haemophilus influenzae type b
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
WO2014100860A2 (en) * 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
EP3439704A1 (de) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogene zusammensetzungen
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
WO2018048869A1 (en) 2016-09-06 2018-03-15 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
SG11201907402SA (en) 2017-03-03 2019-09-27 Treos Bio Zrt Population-based immunogenic peptide identification platform
EP3369431A1 (de) 2017-03-03 2018-09-05 Treos Bio Kft Impfstoff
EP3370065A1 (de) 2017-03-03 2018-09-05 Treos Bio Kft Immunogene peptide
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
EP3876982A1 (de) 2018-11-06 2021-09-15 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
JP2023520562A (ja) 2020-04-03 2023-05-17 ペップティーシー ヴァクシーンズ リミテッド コロナウイルスワクチン
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
DK0626452T3 (da) * 1993-05-17 2000-02-14 Akzo Nobel Nv Vaccine mod infektion af Streptococcus suis
JP4142095B2 (ja) * 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
EP0939648B1 (de) * 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus-impfstoff
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
EP1163008B1 (de) 2003-08-13
ES2200845T3 (es) 2004-03-16
DE60004496T2 (de) 2004-04-08
FR2791895A1 (fr) 2000-10-13
DK1163008T3 (da) 2003-11-17
PT1163008E (pt) 2003-12-31
JP2002540079A (ja) 2002-11-26
FR2791895B1 (fr) 2001-06-15
WO2000056365A1 (fr) 2000-09-28
EP1163008A1 (de) 2001-12-19
CA2366869A1 (en) 2000-09-28
AU3438900A (en) 2000-10-09
ATE246937T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
DE60004496D1 (de) Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
IL210392A0 (en) Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
DE69819332D1 (de) VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN
DE60018907D1 (de) Verfahren und zusammensetzung zur zementierung von bohrlöchern
DE69842240D1 (de) Gerät zur verankerung von objekten an knochen
DE69936948D1 (de) Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE60100473D1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE69833134D1 (de) Verwendung aliphatischer amine zur verminderung von oxalat
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE60144145D1 (de) Subtilisin-variante
ATE353138T1 (de) Verfahren zur stabilisierung und messung von troponinkomplexen
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
GEP20043349B (en) Methods of Controlling Cutworm Pests
DE59804785D1 (de) Verbessertes Verfahren zur Stabilisierung von Proteinen
DE69838667D1 (de) Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE274185T1 (de) Verfahren und zusammensetzungen zur trennung von biologischen makromolekülen
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE69807612T2 (de) Verfahren und Gerät zur Speicherung und Verwendung von ausführbaren Programmen
DE59915124D1 (de) Verfahren zur darstellung von gelände
ATE340249T1 (de) Produkt zur proteinstabilisierung von weinen
SE9604439D0 (sv) New receptor
DE69805298D1 (de) Verbessertes verfahren zur kryopreservierung von pferdeembryonen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8339 Ceased/non-payment of the annual fee